-+ 0.00%
-+ 0.00%
-+ 0.00%
Eli Lilly Agrees to Buy Calytrix Bio in up to $1.5 Billion Deal
Share
Listen to the news
08:02 AM EST, 11/16/2026 (MT Newswires) -- Eli Lilly (LLY.F, LLY.SW) agreed to acquire US biotechnology company Calytrix Bio, according to a Monday release. The US pharmaceutical company could pay up to $1.5 billion in cash, including upfront and additional clinical and regulatory milestone payments. The acquisition will expand Eli Lilly's pipeline of treatments for rare blood cancers known as myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending